|
|
|
시장보고서
Next-Generation Immunoassays: A Market and Technical Analysis of Research Applications 07
|
Abstract
The immunoassay assay is undergoing a major makeover. New amplification
methods offer the promise to peer deeper into the proteome; new detection
methods offer the promise to see clearer; new multiplexing to look faster and
more efficiently; and new content to observe farther. These new technologies
are addressing significant unmet needs in sensitivity, accuracy, speed, cost
and breadth.
This new report details the opportunities and challenges in a market valued at
more than $1.1 billion in 2003 and projected to grow to more than $2.2 billion
in 2012. The report is based on surveys of researchers and thorough
evaluations of more than 70 technologies encompassing novel antibody
generation, real-time detection, new amplification methods and multiplexed
antibody arrays. The financial projections are based on a 3 by 5 market matrix
model encompassing instruments, antibodies and other reagents and consumables
across ELISAs, Western blots, immunoprecipitations, antibody arrays and novel
antibody characterization methods.
In addition, the report comes with an hour of discussion (pending availability
and limited to a conference call format) with Steven Bodovitz, Principal of
BioPerspectives, or Jutta Bachmann, CEO of Bachmann Consulting.
Table of Contents
Table of contents
Chapter 1: Executive Summary
Chapter 2: Introduction to Immunoassays
- Introduction
- Types of Immunoassays
- Western Blots
- Immunoprecipitation
- ELISAs
- Antibody Arrays
- Immunohistochemistry
- Detection
- Immunoassay Characterization
Chapter 3: Opportunities and Challenges for Next-Generation Technologies
- Sensitivity
- Accuracy
- Content
- Multiplexing
Chapter 4: Market Model
- Overall Market
- Market Drivers
- Market Sizes
- Total Market
- ELISAs
- Western Blots
- Immunoprecipitations
- Antibody Arrays
- Other Characterization
- Total By Component
Chapter 5: Company Profiles
- Array companies
- Abbott Molecular, Inc.
- Applied Biosystems
- Bangs Laboratories
- Beckman Coulter, Inc.
- Bender Medsystems GmbH
- Biocept, Inc.
- Bio-Rad Laboratories
- Bioarray Solutions, Ltd.
- Biosource International
- bmd - BioMedical Diagnostics
- DiagnoSwiss S.A.
- GenTel Biosciences, Inc.
- Gyros AB
- Hypromatrix, Inc.
- Illumina, Inc.
- Invitrogen Corporation
- Luminex Corporation
- Marligen Biosciences, Inc.
- Merck Chemicals Ltd./EMD Chemicals, Inc
- Meso Scale Discovery
- Microbionix GmbH
- Millipore Corporation
- Upstate Group LLC (now part of Millipore)
- MiraiBio, Inc.
- Multimetrix GmbH
- One Lambda, Inc.
- Osmetech Inc./plc
- Perbio Science
- PerkinElmer, Inc.
- Protagen AG
- Radix BioSolutions
- Randox Laboratories Ltd.
- RayBiotech, Inc.
- Rules-Based Medicine, Inc.
- Sigma-Aldrich Corporation
- US Biomax, Inc.
- VBC-GENOMICS Bioscience Research GmbH
- Whatman plc
- Zeus Scientific, Inc.
- Antibody companies
- Affibody AB
- AbD Serotec, a Division of MorphoSys
- Aspira Biosystems, Inc.
- Domantis
- Eurogentec S.A.
- Epitome Biosystems
- Epitomics, Inc.
- Human Protein Atlas
- Imgenex Corporation
- Primorigen Biosciences LLC
- R&D Systems, Inc.
- Real-time detection companies
- ACEA Biosciences
- Axela Biosensors, Inc.
- Biodesy, LLC
- Bioforce Nanosciences, Inc.
- Cell Biosciences
- Corning Incorporated
- CSEM SA
- Farfield Scientific
- ForteBio Inc.
- GE Healthcare (formerly Biacore International AB)
- GWC Technologies, Inc
- Plexera Bioscience LLC
- MDS Sciex
- SRU Biosystems
- Amplification companies
- American Dye Source
- BioPAL, Inc.
- BioVeris Corporation (now part of Roche)
- Chimera Biotec GmbH
- Dendritic Nanotechnologies, Inc.
- Evident Technologies
- Lumiphore, Inc
- Monogram Biosciences, Inc
- Nanosphere, Inc.
- Olink Bioscience
- QIAGEN N.V./GmbH
- SRI International
Author credentials
Glossary
Index
|
 |
